Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update.
Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year.
He concentrates on the discussions that are ongoing with potential US out-licensing partners for Accrufer in the States (Feraccru).
